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Induction of synthetic lethality in mutant KRAS cells for non-small
cell lung cancers chemoprevention and therapy
Publication No. _____________
By Shaoyi Huang
Advisor: Xiangwei Wu, Ph.D.
Lung cancer is the leading cause of cancer death in both men and women in the United States and
worldwide. Despite improvement in treatment strategies, the 5-year survival rate of lung cancer
patients remains low. Thus, effective chemoprevention and treatment approaches are sorely
needed. Mutations and activation of KRAS occur frequently in tobacco users and the early stage of
development of non-small cell lung cancers (NSCLC). So they are thought to be the primary driver
for lung carcinogenesis. My work showed that KRAS mutations and activations modulated the
expression of TNF-related apoptosis-inducing ligand (TRAIL) receptors by up-regulating death
receptors and down-regulating decoy receptors. In addition, we showed that KRAS suppresses
cellular FADD-like IL-1β-converting enzyme (FLICE)-like inhibitory protein (c-FLIP) expression
through activation of ERK/MAPK-mediated activation of c-MYC which means the mutant KRAS cells
could be specifically targeted via TRAIL induced apoptosis. The expression level of Inhibitors of
Apoptosis Proteins (IAPs) in mutant KRAS cells is usually high which could be overcome by the
second mitochondria-derived activator of caspases (Smac) mimetic. So the combination of TRAIL
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and Smac mimetic induced the synthetic lethal reaction specifically in the mutant-KRAS cells but
not in normal lung cells and wild-type KRAS lung cancer cells. Therefore, a synthetic lethal
interaction among TRAIL, Smac mimetic and KRAS mutations could be used as an approach for
chemoprevention and treatment of NSCLC with KRAS mutations. Further data in animal
experiments showed that short-term, intermittent treatment with TRAIL and Smac mimetic induced
apoptosis in mutant KRAS cells and reduced tumor burden in a KRAS-induced pre-malignancy
model and mutant KRAS NSCLC xenograft models. These results show the great potential benefit of
a selective therapeutic approach for the chemoprevention and treatment of NSCLC with KRAS
mutations.
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CHAPTER 1 INTRODUCTION
1.1 Lung cancer
Lung cancer, cancer originating in the lung or bronchus, remains the leading
cause of cancer death in the United States and worldwide despite over 30 years of progress
in early detection and standard treatment1. According to the American Cancer Society
estimation, lung and bronchus cancers rank the second place in new increased cases and
accounts for the most death caused by cancer in 2012 for both female and male (Fig. 1)2.
Broadly, it is divided into 2 types according to the pathology: small-cell lung cancer (SCLC)
and non-small-cell lung cancer (NSCLC) 3.
SCLC is an undifferentiated or low differentiated neoplasm composed of
primary cell-like cells 3,4. The cancer cells are usually smaller than normal cells due to
mutations in the pathways controlling cell size. The mutations causing the uncontrolled cell
growth majorly include retinoblastoma (RB) and P53 gene mutations 5,6,7. Other oncogenes
overexpression, like c-MET, MYC and BCL2, were also strongly associated with SCLC 5,8-10.
SCLC occurs almost exclusively in smokers and is highly aggressive due to the low
differentiation grade. It is rapidly growing, and approximately 80% of patients have
metastatic disease at the time of diagnosis 3,4,11. Even though the SCLC is very responsive
to chemotherapy and radiation therapy, such as platinum-containing agents, the tumors
come back quickly in most patients12. The mechanism of drug resistance in SCLC is
complicated and involved multiple factors, such as membrane protein drug pumps
overexpression, enhanced cell DNA repair system and dysfunction of apoptosis system13-15.
1

So SCLC is very malignant and has bad prognosis. Fortunately, it only accounts for about 1520% lung cancer cases (Fig.2)1,3.

Figure 1. The estimated new cases and death caused by cancers.
(American Cancer Society, Cancer Facts & Figures 2012. Atlanta: American Cancer Society;
2012.)
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Figure 2. Subtype of lung cancer
Besides the SCLC, the most common form of lung cancer is NSCLC, which
accounts for 80-85% of all lung tumors, including adenocarcinoma (25-35% of cases),
squamous cell carcinoma (30–35%) and large cell carcinoma (10–15%) (Figure 2) 3,16. The
three subtypes of NSCLC are divided according to the cell type of origin, but there can also
be mixed cell types in patients. NSCLC is diverse not only in the subtype, but also in the
genetic background17-20. It usually harbors a single specific mutated oncogene that is
thought to be the primary genetic “driver” gene which leads to tumorigenesis. To date, a
number of driver genes have been identified including: KRAS, BRAF, MEK1/2, epidermal
growth factor receptor (EGFR), HER2, PI3K and EML4-ALK 3,17-20. Among those genes,
mutation of KRAS is found in 25-30% of NSCLC17.

3

1.2 RAS mutations in lung cancer
RAS gene was firstly discovered during the study of cancer-causing viruses in
animals (Harvey JJ 1964, Kirsten 1967) 21-22. Then it got the name from the rat sarcoma (Ras)
and two discoverers, Harvey ras (H-Ras) and Kirsten ras (K-Ras). There was also another Ras
found later in human neuroblastoma cells, so called N-Ras 23. RAS, KRAS and NRAS all
belong to the RAS family, which encode a family of membrane-bound 21-kd guanosine
triphosphate (GTP)-binding proteins 24. Those highly homologous proteins are all GTPases
that act as molecular on/off switch. After binding to GTP with the help from guanine
nucleotide exchange factors (GEFs), those RAS proteins will recruit and activate various
downstream proteins, such as PI3K and RAF-MEK-ERK, to provide the survival and
proliferation signals for the cells 24-26. Because of the intrinsic GTPase activity of RAS, it will
hydrolyze the bound GTP into GDP with the help of GTPase activating proteins (GAPs).
Then the GDP-bound form is inactive for downstream signaling 24,27.
If there are any mutations in RAS which prevent the GTPase activity of RAS,
the RAS will be always RAS-GTP form and constitutively active. The most common gain
function mutations in RAS include residue G12, G13 and Q61 28. The mutations at residue
12 and 13 would attenuate the interaction of GAP to RAS and then block the hydrolysis of
GTP by RAS protein, while the mutations at residue 61 directly abolish the hydrolysis
activity of RAS 28-31. Upon those mutations, RAS proteins were constitutively “on” and the
downstream signaling will be activated inappropriately, which can modulate cell growth,
differentiation, and apoptosis through linked receptor and non-receptor tyrosine kinases,
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and finally cause the tumorigenesis 24, 29. This is accomplished through multiple effectors
including Mitogen-activated protein kinase (MAPK), Signal transducer and activator of
transcription (STAT) and Phosphoinositide 3-kinase (PI3K) signaling cascades (Fig. 3) 24-26, 32.
Mutations in genes which are upstream of RAS can have similar effect as well as RAS
mutation, such as BCR-ABL or EGFR 33-36.

Figure 3. The RAS signaling casecades.
RAS mutations have been found in approximately 30% of all human cancers,
including mutations in NRAS, HRAS and KRAS 24, 29. Since the downstream signals of RAS
genes vary by family members, there is some correlation between specific tumor type and
RAS gene mutation 29, 37. For example, in adenocarcinoma of the lung, pancreas and colon,
the KRAS gene is the predominantly mutated member of the RAS family, whereas in
5

myeloid leukemia it is primarily NRAS that is mutated 38-41. HRAS mutations may be related
to bladder and kidney cancers 42-43.
KRAS mutations account for most of the cancer-related RAS mutations in
NSCLCs 38. The studies revealed that KRAS mutations accounts for 90% of RAS mutations in
lung adenocarcinomas and approximately 97% of KRAS mutations in NSCLC involve codons
12 or 13, while KRAS mutations are rare in lung squamous cell cancer 44, 45. Recent study
suggests that KRAS mutations are associated with a worse overall survival in patients with
NSCLC, especially in patients with adenocarcinoma and early stage 46-47. And also some
studies suggested that the lung cancers with KRAS mutations are more resistant to
cytotoxic chemotherapy and EGFR-TKIs treatments 48-50. The studies in recent two decades
did not provide any effective way to treat the NSCLC with KRAS mutations.

1.3 Lung cancer treatment
Symptoms of lung cancer include cough, chest pain and weight loss. However,
many patients present with metastatic cancer having no obvious clinical symptoms.
Diagnosis is typically made by chest x-ray or CT and confirmed by biopsy. Most NSCLC
patients are detected when the cancer is already advanced 51. Depending on the stage of
the disease, treatment may include surgery, chemotherapy, radiation therapy, or a
combination. For the past several decades, the prognosis for a lung cancer patient was
poor, with only 15% of patients surviving > 5 year from the time of diagnosis 52. For
patients with stage IV (metastatic) disease, the 5-year overall survival rate was < 1% 52.
6

However, the identification of certain mutations that can be targeted for therapy, has
recently improved outcomes.
Targeted therapy has been established for the treatment of advanced NSCLC,
such as treatment with erlotinib (Tarceva) after chemotherapy, which targets the EGFR
mutation. But since KRAS is downstream effector of EGFR, the erlotinib has little benefit for
those NSCLC patients with KRAS mutation 48-50. In recent years, several new targeted
therapies have been developed for KRAS mutation, such as the MEK1/2 inhibitor AZD6244
(Selumetinib) 53, the BRAF inhibitor Sorafenib (Nexavar; BAY 43-9006) 54 and the Farnesyl
Transferase Inhibitors (FTIs) 55-56.
The MEK1/2 inhibitor and BRAF inhibitor function via directly binding to the
MEK1/2 and BRAF individually and inhibiting the Kinase activity. The study on the MEK1/2
and BRAF inhibitors showed that the combination of Selumetinib plus docetaxel as the
second-line treatment of KRAS mutated NSCLC significantly improved outcomes. The
primary end point of overall survival was increased from 5.2 months to 9.4 months 57. A
Phase II clinical trial of Sorafenib for the treatment of NSCLC in 2012 also showed some
efficacy 58. The primary end point of overall survival from time of randomization was 13.7
months in the treated group versus 9.0 months in placebo group 58.
The FTIs can bind to farnesyl transferase (FFTase) and inhibit the farnesylation
of KRAS on the C-terminal of protein. The post-transcription modification of KRAS,
including farnesylation, methylation and palmitylation, will associate KRAS protein to inner
face of the plasma membrane, which is essential for RAS interaction with other proteins 59.
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Several Farnesyl Transferase inhibitors had been tested in clinical trials, including
lonafarnib (SCH-66336), R115777 and L-778,123 60-62. Even those inhibitors showed the
anti-cancer activity in pre-clinical experiments and some phase I/II studies, there was no
improvement in overall survival in phase II/III studies 56. The failure of FTIs may be due to
the alterations of farnesylation of KRAS, such as myristylation and geranylgeranylation,
which will also associate the KRAS protein to the memberane 63.
These outcomes for KRAS targeted therapy are promising but not very
impressive. In contrast, treatment with crizotinib led to an overall survival of about 24
months in patients with an (anaplastic lymphoma kinase) ALK rearrangement, while
treatment with erlotinib increased overall survival to about 27 months in patients with an
EGFR mutation 64-65. The KRAS targeting drugs also had some side effects, which cause
decreased dose or interrupted dose 66. Toxicity concerns, together with the relatively
modest increase in survival of current KRAS targeted therapies, highlight the urgent need
to develop new strategies or drugs targeting KRAS mutant NSCLC.

1.4 Lung cancer chemoprevention
KRAS mutations are not only found in cancers but also in individuals at risk
(but without cancer) who have significant tobacco exposure and are detected in 25%–40%
of atypical adenomatous hyperplasia lesions, which are a potential precursor of
adenocarcinoma 67. This suggests that KRAS mutations exist not only in advanced NSCLC,
but also appear to be an early event in human NSCLC development, and may be regarded
8

as the driving event of NSCLC 67-70. So KRAS mutations could be the good target for cancer
chemoprevention.
Cancer chemoprevention is the use of synthesized drugs or natural
compounds to suppress or slow down the carcinogenesis process or prevent the
recurrence of a tumor after successful treatment 71. Cancer chemoprevention represents
an important facet of cancer research because cancer, especially late-stage cancer, remains
the second killer in U.S.A and worldwide 72. Many years of research has led to great
improvement in our understanding of the molecular mechanisms of cancer and to the
development of various advanced treatment procedures. However, progress has been
slow in the long-term survival rate for patients with most solid tumors. The difficulty in
treating late-stage cancer results from its intrinsic property: genomic instability. The
current chemotherapy and radiotherapy may not kill 100% of the cancer cells and the
remaining cells exhibit poor drug response, which is in part responsible for the high relapse
rates in cancer treatment. Cancer is a multi-step disease, the development of which
requires multiple genetic and epigenetic changes 3, 73. Chemoprevention targets tumor
development at early stages, including tumor initiation and promotion when the cancer
genome remains relatively stable. Since the most difficult obstacle in cancer treatment is
genomic instability, bypassing it using this approach holds great potential.
However, only a few molecular targets have been identified and the molecular
basis for chemoprevention is poorly understood. To date only about 13 agents are FDA
approved for cancer chemoprevention. They include Tamoxifen, Raloxifene, HPV vaccine,
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Celecoxib and Fluorouracil 74. Tamoxifen and Raloxifene are approved to reduce the risk of
breast cancer incidence in high-risk women 75-76. The HPV vaccine is approved for the
prevention of cervical and anal cancers caused by HPVs 77. Celexcoxib is a non-steroidal
anti-inflammatory drug (NSAID) and specific COX-2 inhibitor which has been shown to
decrease the number of adenomatous colorectal polyps in FAP patients as an adjuvant to
regular care (such as endoscopic surveillance and surgery) 78. Fluorouracil (5Fu) is used as a
chemotherapy drug to treat several types of cancer including colon, rectum, and head and
neck cancers. It was recently approved by the FDA for topical treatment of actinic keratosis
(AKs) 79. Untreated AKs can become squamous cell carcinomas (SCC), the second most
common form of skin cancer. In addition to these approved drugs, more agents are being
investigated in labs for use in chemoprevention 74, 80-82. Phytochemicals, including
curcurmin and genistein, represent a popular class of potential chemoprevention agents 8384

. Based on epidemiological studies, it has been demonstrated that these compounds have

anti-inflammatory activities and can reduce the risk of carcinogenesis 85.
Despite the handful of FDA approved chemoprevention drugs, there are still a
lot of difficulties in current chemoprevention strategies. For those phytochemicals, the
mechanism of anti-inflammatory activity remains unclear. Without a precise assessment of
the mechanisms, it is unlikely that phytochemicals will be recommended for testing in
human clinical trials. Even for those approved chemoprevention drugs; successful
treatment requires long-term administration, which can lead to toxicity, high cost and
resistance. For lung cancer, some agents, such as COX2 inhibitors, have shown activity
against lung cancer in animal 86. However, in clinical trials the effect is not very obvious and
10

long-term continuous administration is required, which causes safety concerns 87. Even the
approved chemoprevention drugs, Tamoxifen and Raloxifene, achieved 50-70% reduction
in incidence of invasive breast cancer in the treatment arm, toxicity and resistance are still
notable concerns 74, 88. In an effort to overcome these challenges, we need to develop new
chemoprevention approaches that can specifically target premalignant tumor cells or
malignant tumors.
In the lung cancer field, there are also some drugs and methods being studied
specifically targeting chemoprevention. Several natural products have been tested in
clinical trials for lung cancer chemoprevention in smokers, including beta-carotene, retinol,
Vitamin E or N-acetylcysteine 89-93. Unfortunately, these trials showed either neutral or
harmful primary endpoint results in primary, secondary or tertiary prevention 89-93. Trials of
aspirin and selenium also had little to no positive effect 94-95. Recently, there have been a
number of studies focused on NASIDs for lung cancer chemoprevention, particularly the
COX-2 inhibitors 96-97. This is because inflammation has been correlated with carcinogenesis
and COX-2 over-expression has also been observed in former smokers. Additionally, COX-2
over-expression is shown to be a poor prognostic indicator in NSCLC 98-99. The most wellknown COX-2 inhibitor is celecoxib, which inhibits the production of PGE2 and reduced the
Ki-67 labeling index in active smokers in a phase II clinical trials 100. However, the large
scale chemoprevention trials of celecoxib had only neutral results 96-97. There is still no
clear path for the development of lung cancer specific chemoprevention strategies.
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1.5 SITEP based cancer chemoprevention
For most traditional approaches of chemoprevention, it usually applies the
agents to modulate the tumorigenic pathways rather than eliminate large numbers of
premalignant or malignant cells, which will also affect the normal cells 101. To keep the
toxicity to the minimum or the lowest tolerated level of patients, only very limited dose of
agents had been applied for chemoprevention, which will lead to low efficacy. To maintain
the efficacy of chemoprevention, long term continuous or near continuous treatment could
not be avoided, which will cause the accumulated toxicity and bring some unexpected side
effects.
In contrast to those traditional long term and continuous dosing treatment
for chemoprevention, a new idea called short-term intermittent therapy to eliminate
premalignancy (SITEP) has been raised based on the synthetic lethality strategy 102. The
core goal of SITEP is to reduce the long-term toxicity, while maximizing efficacy, by using
short term and intermittent treatment to prevent cancer. This goal can be achieved
because of the nature of carcinogenesis. Carcinogenesis is a multistep process that involves
the accumulation of many genetic and epigenetic changes 3, 73, 89. Typically only a few
crucial mutations will drive normal cells to become premalignant cells and finally malignant
cells. The SITEP approach is to kill the premalignant cells by targeting the crucial mutations
via short term and intermittent treatment. Intermittent treatment can reduce the number
of premalignant cells and ultimately decrease the patient’s risk of developing cancer
between treatment cycles (Fig 4).
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Figure 4. The principle of SITEP. The number of premalignant tumor cells is
positively proportional to the cancer risk in patients. Intermittently eliminating
premalignant tumor cells with short time treatment should dramatically decrease
the cancer risk and subsequently inhibit or delay cancer development.
(Xiangwei Wu and Scott M. Lippman, Nature Reviews:Cancer, 2011, vol 11)

1.6 Synthetic lethality
One of the key factors for SITEP is to eliminate a large numbers of
premalignant cells by a short term treatments. That requires potent and selective killing
effects on the premalignant cells in a short time. Synthetic lethality might be an
appropriate strategy for that purpose.
Synthetic lethality means the cell death could be induced by the combination
of mutations in two or more sensitive genes, while mutation of single gene alone is not
sufficient to induce cell death 102. Compared to the current cytotoxic drugs, the synthetic
lethality approach has the advantage of inducing apoptosis selectively and precisely in
those mutated cells while not harming the normal cells. Compared to the current targeted
therapy drugs, such as the kinase inhibitors or antagonists, synthetic lethality has the
13

advantage of changing the targeting effect from cytostatic to cell death, which is more
efficient and less toxic. Based on the idea of synthetic lethality, it is recently reported that
apoptosis could be induced specifically in the premalignant cells with particular gene
mutations, BRCA1/2 mutation 103. Poly (ADP-ribose) polymerase (PARP) inhibitors hinder
base-excision repair and cause cell death in BRCA1/2 deficient cells due to DNA damage
and could be used to target the BRCA1/2 mutant breast premalignant cells. Our lab also
reported that Retinoic Acid (RAc) plus TRAIL, which targets the APC deficient colorectal
premalignant cells, have the potential to be effective chemopreventive agents 104. RAc plus
TRAIL induces apoptosis only in the APC deficient cells due to the up-regulated cMyc level,
resulting in reduced cFLIP levels, will sensitize the cells to TRAIL triggered extrinsic
apoptosis. The outcome of animal experiments with APC/Min mice has proved the great
potential for chemoprevention.

1.7 Apoptotic pathway and TRAIL
Apoptosis is one type of Programmed Cell Death (PCD) which exists in
difference organisms 105. It is usually characterized by distinct morphological changes,
energy-dependent biochemical cascades and finally cell 105-106. The morphological changes
include membrane blebbing, cell shrinking, chromatin condensation,
and chromosomal DNA fragmentation 105-106. The intrinsic biochemical processes include
activation of caspase cascades, protein cleavage, protein cross-linking and DNA breakdown
105-107

.
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Caspases are a family of proteases which are able to cleave proteins at aspartic
acid residues 108. So far about 10 caspases have been identified and categorized into 3
groups. They are initiators (caspase-2,-8,-9,-10), effectors or executioners (caspase-3,-6,-7)
and inflammatory caspases (caspase-1,-4,-5) (14). Pro-caspases can be activated through
either intrinsic or extrinsic apoptotic pathways by cleavage 108-109. The intrinsic apoptotic
pathway activates caspases via permeabilization of the mitochondria and release of proapoptotic proteins into the cytoplasm, such as cytochrome c, Apaf-1 and second
mitochondria-derived activator of caspase (Smac) 110-112. Cytochrome c and Apaf-1 form a
multi-protein complex known as the “apoptosome” and initiate activation of the caspase
cascade through cleavage of caspase-9 111. The extrinsic apoptotic pathway activates the
caspases via transmembrane death receptors such as tumour necrosis factor receptor 1
(TNFR1), Fas/CD95 and TRAIL receptors (DR4/5) 112-113. As death ligands bind to these
receptors, the death inducing signaling complex (DISC) is formed leading to initiation of the
caspase cascade through cleavage of caspase-8/10 114. Once caspase-8/10 is activated, the
downstream caspases are triggered, and the cell undergoes apoptosis 112-114.
Researchers observed apoptotic cells in different cancers and found that a
high rate of apoptosis is correlated with slow growing tumors, and increased apoptosis was
also observed in tumors treated with radiation or chemotherapy 115. Elsewhere,
researchers reported that failure of apoptotic activation may promote cancer growth and
even cause 116-117. This may be the case in tumors with Bcl-2 overexpression not only
survives the removal of growth factors, but is also resistant to chemotherapy 116. Taken
together, this indicates that induction of apoptosis may be an interesting approach for
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cancer treatment. Agents that can restore the apoptotic signaling pathways may
specifically kill the cancer cells, which require these apoptotic defects to survive. A lot of
studies have focused on these agents, which has opened the door into a new type of
anticancer drugs and treatment strategies 118-120. This class of drugs includes Bcl-2/Bcl-xL
inhibitors, Bcl-2/Bcl-xL siRNA, XIAP siRNA and caspase activating drugs. Among them, the
death receptor ligand tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)
is a popular candidate and has great potential 116.
TRAIL was first cloned in the 1996 121 and following studies showed that TRAIL
forms a homotrimer and binds to its death receptors 4 and 5 (DR4, DR5) on the cell surface
122

. Both DR4 and DR5 have 2 extracellular cysteine-rich domains and one cytoplasmic

death domain (DD) 122. Upon binding to TRAIL, DR4 and DR5 also form homotrimers or
heterotrimers and recruit Fas-associated death domain (FADD) through the DD interaction
123-124

. Then FADD recruits amino terminal death effector domain (DED)-containing

apoptosis initiating proteases, caspase-8/10 via its own DED domain 123-124. The cytoplasmic
DD domain of DR4/5, the FADD and the caspase 8/10 form a death-inducing signaling
complex (DISC) 123-124.The formation of DISC will cause caspase-8/10 auto-cleavage and
active, which will trigger the downstream process including cleavage of downstream
effector caspase-3/7 and DNA fragmentation 125. In addition to DR4 and 5, three decoy
receptors of TRAIL, DcR1, DcR2 and OPG, can also interact with TRAIL. These decoy
receptors may exist in both membrane-bound and soluble form 126. When bound to the
membrane, the lack of functional cytoplasmic signaling domains will block the TRAIL
induced death signaling 126. Upon TRAIL binding to DR4 or DR5, death receptor mediated
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apoptosis can be inhibited by a protein called cellular FADD-like IL-1β-converting enzyme
(FLICE)-like inhibitory protein (c-FLIP), which binds to FADD and pro-caspase 8/10 and
prevents the cleavage of pro-casepase 8/10 (Fig.5) 127.

Figure 5. The intrinsic and extrinsic apoptotic pathways of TRAIL
In recent years, TRAIL has shown the great potential as an anti-tumor candidate
by selectively killing a wide variety of human tumor cell lines without harming normal cells
125

. This discovery resulted in the rapid development of cancer therapeutics targeting this

pathway. The TRAIL pathway has been targeted for clinical application by at least two
approaches: recombinant human TRAIL (rhTRAIL) ligand and agonistic antibodies against
DR4 and DR5 126-129. The toxicity of rhTRAIL and the DR4/DR5 monoclonal antibodies
(Mapatumumab and Apomab) has been evaluated in a variety of animal assays, with little
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or no toxicity 128-129. Both rhTRAIL and TRAIL agonists have been moved to in phase II
clinical trials 125. TRAIL showing low toxicity to normal cells usually depends on the
overexpression of decoy receptors to prevent TRAIL–induced apoptosis by either binding
competition or another mechanism 130. Tumor cells frequently develop strategies to resist
TRAIL induced apoptosis, including overexpression of decoy receptor, cFLIP and Inhibitors
of Apoptosis Protein (IAPs) 131-134.

1.8 IAPs and Smac
IAPs belong to a family of proteins which inhibit caspase activation by binding to
them and preventing cleavage of their substrates. All IAPs consist of one or more
baculoviral IAP repeat (BIR) domains while some IAPs also contain a RING domain which
acts as an E3 ubiquitin ligase. X-linked inhibitor of apoptosis (XIAP) and cIAP1/2 are
examples of RING domain containing IAPs. The most well characterized mammalian IAP is
XIAP, which can bind to and inhibit caspases-3, -7 and -9 via its BIR domains (Fig. 6) 135.
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Figure 6. The family of IAPs in mammalian cells
(Stefan J. Riedl and Yigong Shi, Nature Reviews:Molecular Cell Biology, 2004, Vol 5)

To overcome the blockade of IAPs, TRAIL-induced extrinsic apoptotic pathway
therefore requires help from the intrinsic mitochondrial pathway via caspase-8 cleavage of
BH3 interacting domain death agonist (Bid) 136. Truncated Bid (tBid) can interact with Bax
and Bak and induces the oligomerization of Bax and Bak in the mitochondrial membrane,
which leads to activation of the intrinsic apoptotic pathway and release of Smac from the
mitochondria 136. Smac subsequently binds to the BIR domain of the IAPs, relieving the
blockade and leading to apoptosis 137-138.
Smac is a 25-kDa protein which is expressed in mitochondria and is released
during the apoptosis 139. Experiments using recombinant proteins have shown that caspase
inhibition by IAPs can be relieved by the addition of IAP antagonist in vitro 140. Hence the
molecules that mimic the binding interactions between IAPs and Smac, referred to as Smac
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mimetics, are being designed as a novel class of anticancer drugs through targeting IAP
proteins, and thus sensitizing cells to induction of apoptosis. So far there have been
numerous reports showing that different Smac mimetics have strong anticancer activities
141-145

. Several Smac mimetics are being tested in clinical trial, such as TL32711 in phase I

study of adult patients with advanced solid tumors and lymphoma 141. For this drug, no
dose-limiting toxicities have been observed and there is strong evidence of anti-tumor
activity. Other Smac mimetics being tested include LCL161 (Novartis) 142, GDC-0917
(Genentech) 143, HGS1029 (Human Genome Sciences) 144 and AT-406 (Ascenta) 145. Our lab
received Smac mimetics JP1584 from Joyant Pharmaceuticals (Dallas, TX) as a gift. The
JP1584 is a small molecule and the secondary generation of Smac mimetics developed by
Joyant Pharmaceuticals. It is derived from the first generation of Smac mimetics JP1010,
which is a synthesized dimeric peptide (Fig. 7)146.

Figure 7. The Chemical structures of JP1010.

20

1.9 Statement of problem, hypothesis and project goals
Lung cancer is the leading cause of cancer death in both men and women in the
United States. Despite improvement in treatment strategies, the 5-year survival rate of
lung cancer patients remains low. Thus, effective chemoprevention and treatment
approaches are sorely needed.
Recently our lab published a paper in Nature, which reported a synthetic lethal
interaction between TRAIL, RAc and the APC gene (Fig. 5) 104. We showed that TRAIL and
RAc cooperatively induced apoptosis in APC-deficient cells without harming normal cells.
Furthermore, short-term treatment with TRAIL plus RAc significantly reduced polyp
numbers by up to 90% in APC-deficient mice. These results suggest that the combination of
TRAIL and RAc have great potential in eliminating premalignant tumor cells and preventing
tumor-related death in these animals.
The APC-deficiency mediated cMyc up-regulation is the key factor that sensitizes
the cells to TRAIL plus RAc combination treatment. It was also reported that KRAS
activation can up-regulate cMyc 147. Considering the fact that mutations and activation of
KRAS occurs frequently in NSCLC and these changes are thought to be primary drivers for
lung carcinogenesis, I hypothesized that the premalignant lung cells and lung cancer cells
with KRAS mutations could be specifically targeted for TRAIL induced apoptosis (Fig.8).
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Figure 8. Synthetic lethal interaction between TRAIL, RAc, Smac mimetic and KRAS
The Inhibitors of Apoptosis Proteins (IAPs) in those cells with abnormal KRAS
activation are usually up-regulated to antagonize apoptosis. The blockade can be overcome
by the Smac mimetics, as reported in the literature 132. Since KRAS mutation is also
preserved in malignant stages, it is reasonable to propose that combination treatment
could also be efficacious in the treatment of cancer.
Pursuing a new approach to specifically kill premalignant cancer cells would
enable us to develop a more effective strategy for cancer prevention. In this way, we could
make chemoprevention work like therapy to reduce the duration of treatment. The SITEP
approach, applying synthetic lethality to target KRAS dys-regulation, will also minimize the
potential side effects and reduce the costs associated with long-term therapy.
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Given this information, we hypothesize that the co-treatment of TRAIL, RAc and
Smac mimetic will induce a synthetic lethal interaction specifically in the mutant-KRAS cells,
and that this approach may be applied as a new method to prevent and treat NSCLC with
KRAS mutation.
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CHAPTER 2 MATERIALS AND METHODS
2.1 Cell culture
The immortalized human bronchial epithelial (HBE) cell line HBE4-E6/E7 (HBE4)
was purchased from ATCC. BW1799 cells were kindly provided by Dr. Reuben Lotan of M.D.
Anderson Cancer Center and were maintained in Keratinocyte-SFM medium (Life
Technology, Grand Island, NY). Lung cancer cell lines NCI-H322, NCI-H661, NCI-H460, NCIH358, NCI-H157, A549, NCI-H2122 and NCI-H1299 were all purchased from ATCC and
maintained in RPMI 1640 medium (Thermo Scientific , Rockford, IL) supplemented with 10%
Fetal Bovine Serum (FBS) and 1% antibiotics (penicillin/streptomycin).

2.2 Plasmids, shRNAs, and reagents
The retroviral plasmid expressing a mutant KRAS (KRASV12) was reported in
previous paper 156 and generously provided by Dr. Jinsong Liu from UT M.D. Anderson
Cancer Center. ERK dominant-negative and AKT/PKB dominant-negative constructs were
generously provided by Dr. Mien-Chie Hung from UT M.D. Anderson Cancer Center. The
long form c-FLIP construct was generated in pcDNA3.1 (Life Technology, Grand Island, NY)
by cloning cellular c-FLIP cDNA from total RNA of Hela cells, as previously reported 136.The
DR5 expression plasmid was provided by W. El-Deiry. The c-Myc-shRNA was generated in
pSUPER and the target sequence is 5’-TTCAAGAGA-3’ 104. XIAP-shRNA was purchased from
Open Biosystems. Recombinant soluble rhTRAIL protein was purified according to
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published methods157. In the purification, the B-PER buffer and Ni-NTA agarose were
purchased from Thermo Scientific 146. The Fluorouracil (5Fu) was purchased from Sigma (St.
Louis, MO). U0126 and Wortmannin were purchased from CalBiochem (Billerica, MA).

2.3 Antibodies
Anti–c-FLIP monoclonal antibody was purchased from ALEXIS Biochemicals
(Farmingdale, NY). Anti–phospho-ERK, anti–phospho-AKT, anti–cleaved CASPASE 3, antiCASPASE 8 and anti-DR5 antibodies were purchased from Cell Signaling Technology
(Danvers, MA). Anti–c-MYC and Anti-DR4 antibody was purchased from Millipore (Billerica,
MA). Anti–β-Actin and anti–α-TUBULIN antibodies were purchased from Sigma (St. Louis,
MO). Antibodies against DCR1 and DCR2 were purchased from Imgenex (San Diego, CA).
Anti-XIAP, anti-BCL2 and anti-BCL-XL antibodies were purchased from BD Transduction
Laboratories (San Jose, CA).

2.4 Infection, transfection, and drug treatment
Retrovirus was generated by using the BOSC23 packaging cell line, and
infection was carried out as reported previously 158. Transfections were carried out by using
Lipofectamine 2000 (Life Technology, Grand Island, NY) according to the manufacturer’s
instructions. For TRAIL and Smac mimetic treatment, cells growing in log phase were
treated with Smac mimetic at a final concentration of 100nmol/L for 30 minutes. Then
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TRAIL was added to the media at a final concentration of 100ng/mL. For 5-Fu treatment,
cells growing in log phase were treated with 5-Fu at a final concentration of 5ug/mL for 1216 hours. Cells were harvested after 24 hours of TRAIL treatment. Where indicated, cells
were treated with Wortmannin (200 nmol/L) and U0126 (10 mmol/L) for 30 minutes. Cell
viability was determined by using Annexin V-FITC Apoptosis Detection Kit (Sigma, St. Louis,
MO) according to the manufacturer’s instructions.

2.5 Mouse Model for Tumorigenesis
Breeding colonies were established from LSL-KrasG12D mice acquired from the
Mouse Repository of the National Cancer Institute. AdenoCre virus was purchased from the
Gene Therapy Core of Baylor College of Medicine. Mice were infected according to a
previously reported protocol 159-160. In brief, AdenoCre-calcium phosphate (AdCre-CaPi)
precipitates were prepared by placing recombinant adenovirus in 1 mL of Eagle’s minimal
essential media containing 1.8 mmol/L Ca2+ and 0.86 mmol/L Pi. Then an aliquot of a 2
mol/L CaCl2 solution was added to achieve a concentration of 4.5 mmol/L Ca2+. The
solution was mixed by vortex or gentle pipetting, and the mixture was allowed to incubate
for 20 to 30 minutes at room temperature. G12D mice were anesthetized with avertin at 812 weeks of age. AdCre-CaPi coprecipitates [5 - 108 pfu (plaque forming units)] were
administered intranasally in two 62.5-µL instillations. The second instillation was
administered when breathing rates had returned to normal following the first
administration. Six weeks after infection, the mice were injected intravenously with Smac
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mimetic (3 mg/kg). Six hours later, TRAIL (3 mg/kg) was administerd by intraperitoneal (i.p.)
injections. This regimen was repeated 18 hours later. Consecutive injections of TRAIL and
Smac mimetic were given a total of 3 times. Injection of PBS was used as a control. For
intermittent treatment, the mice were given 3 consecutive injections of TRAIL and Smac
mimetic (1.5 mg/kg) within a week, left off treatment for 3 weeks, followed by another
week of injections, for a total of 3 treatment cycles. The mice were sacrificed 1 day after
the last treatment, and their lungs were inflated with formalin and fixed in formalin
overnight.
For the xenograft model, male athymic nude mice aged 2 months were
purchased from Jackson Labs. The nude mice were inoculated subcutaneously at the right
flank with 1 x 106 NCI-H322, or NCI-H460 cells in 100 μl of PBS 161. Treatment was started
once the solid tumor reached 5 mm, mean diameter (about 12 days after NCI-H322 or NCIH460 incubation). In treated group, 3 mice were injected intravenously with Smac mimetic
(3 mg/kg). Six hours later, TRAIL (6 mg/kg) was injected i.p.. Injections were repeated 18
hours later. Consecutive injections of TRAIL and Smac mimetic were given every another
day for a total of 6 treatments. To minimize measurement variability, tumors were
measured every 3 days, by a single individual using the same calipers. Tumor volume was
calculated using the following formula: V (mm3) = [width2 (mm) x length (mm) x π]/6. On
day 24, mice were sacrificed and tumors were fixed in formalin overnight. All animal
experiments were conducted according to the ethical standards of the U.T.MD Anderson
Cancer Center Animal Care and Use Committee (ACUC).
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2.6 HE and IHC staining
Lung sections were analyzed by hematoxylin and eosin (HE) and
immunohistochemistry (IHC) staining using an anti–cleaved caspase 3 antibody. Tissue
sections were de-paraffinized and rehydrated in an ethanol series. For HE staining, sections
were stained in Mayer’s hematoxylin solution (Sigma, St. Louis, MO) for 2 min, then rinsed
in 0.1% HCl-ethanol solution for 2 sec. The differentiation will take about 5 min in running
tap water. Then the sections were stained in eosin Y solution 0.1% aqueous (Sigma, St.
Louis, MO) for 3-5 min and rinsed in tap water for 30-45 sec. After checking the staining
quality under the microscope, the sections were dehydrated again and mounted with
mounting medium (Vector labs, Burlingame, CA). For IHC staining, the sections were
blocked for non-specific binding with 5% goat serum and incubated with the primary anticleaved caspase 3 antibody for overnight at 4°C. On the second day, the sections were
incubated with biotinylated secondary antibody for 1 hour at 37°C and then
Avidin/Biotinylated HRP complex (Vector labs, Burlingame, CA) for 1 hour at 37°C. The DAB
development were operated with the DAB Kit (Vector labs, Burlingame, CA) according to
the manufactory instructions.

2.7 TUNEL assay
Apoptosis in tumor sections was analyzed using Terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) staining with the kit from Sigma (St. Louis, MO).
Tissue sections were de-paraffinized and rehydrated in an ethanol series. Pre-treat the
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sections with proteinase K solution from the kit and incubate the sections with TdT
reaction mixture for 1 hour at 37°C. Stop the reaction with stop solution and rinse the
sections with PBS. Finally the sections were counterstained with 4’,6’-diamidinio-2phenylindole (DAPI) and mounted with Vectashield hard set mounting medium (Vector labs,
Burlingame, CA).

2.8 Statistical analysis
We compared differences between groups via 1-way ANOVA. Values with a P
< 0.05 were considered to be statistically significant.
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CHAPTER 3 Use TRAIL and Smac mimetic for lung cancer
chemoprevention
KRAS mutations are found in individuals who have significant tobacco
exposure and also detected in 25-40% atypical adenomatous hyperplasia lesions, which
suggests that KRAS mutations is an early event in human NSCLC development. And also it is
reported that KRAS is one of the most important driver genes in NSCLC tumorigenesis 19. So
we targeted KRAS mutations for NSCLC chemoprevention. In this chapter, first I tested the
response of normal lung epithelial cells with KRAS activation to TRAIL and Smac mimetic.
Then I dissected the molecular basis behind the response. After confirming the effect of
TRAIL and Smac mimetic co-treatment in vitro, I also evaluate the efficacy of the TRAIL and
Smac mimetic co-treatment in vivo within the LSL–K-RAS G12D mice.

3.1 TRAIL and Smac mimetics specifically induce apoptosis in KRAS-activated HBE4 and
BW1799 cells.
To test if TRAIL and Smac mimetics combination can eliminate the
premalignant lung cells, we need to establish an in vitro model of the premalignant lung
cancer cells. So here we introduced the activating mutant KRASG12V into the immortalized
normal lung epithelia cell lines HBE4 and BW1799. Signaling downstream of KRAS,
including Erk and AKT, was increased following constitutive expression of mutant KRAS in
HBE4 and BW1799 cell lines (Fig. 9A). Then, to test whether KRAS activation sensitizes
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normal lung epithelial cells to TRAIL plus Smac mimetics–induced apoptosis, HBE4 cells
transfected with vehicle or mutant KRAS plasmid were treated by Smac mimetic for 30min,
then followed by TRAIL treatment or by Smac mimetic or TRAIL treatment individually.
After 24 hours post TRAIL treatment, the apoptotic cells were determined with annexin VFITC apoptosis detection kit. Results showed that HBE4 cells transfected with vehicle
plasmid are resistant to apoptosis induced by TRAIL, Smac mimetic or the combination (Fig.
9B), while cells transfected with mutant KRAS are sensitive to TRAIL plus Smac mimetic–
induced apoptosis but not the single treatment (Fig. 9B). Similar results were observed in
BW1799 cells (Fig. 9C). These results indicate that activation of KRAS specifically sensitizes
normal lung epithelial cells to the induction of apoptosis by the combination of TRAIL and
Smac mimetic.
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Figure 9. Mutant KRAS activates downstream-signaling pathways and sensitizes
normal cells to TRAIL and Smac mimetics. A, overexpression of mutant KRAS and
induction of phosphorylation of ERK (p-ERK) and AKT (p-AKT) in BW1799 and HBE4
cells. These cells were infected with either vehicle retrovirus (Vec) or mutant KRAS
expressing-retrovirus. B&C, induction of apoptosis by TRAIL and Smac mimetics.
HBE4 cells and BW1799 cells expressing mutant KRAS were treated with TRAIL
(100 ng/mL) or Smac mimetics (100 nmol/L) or both or control (PBS) for 24 hours.
Apoptotic cells (Annexin V+/PI-) were counted. The data represent results from 3
independent experiments. Averages and SD are shown.
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3.2 Mutant KRAS up-regulates TRAIL receptor levels to facilitate TRAIL-induced
apoptosis in normal cells.
Even we hypothesize the synthetic lethality will be generated by combination of
TRAIL, RAc and Smac mimetic, previous results showed that the combination of TRAIL and
Smac mimetic can induce apoptosis in the normal lung epithelial cells with KRAS activation
independent of RAc. Then I tested the role of RAc in normal lung epithelial cells as well as
APC deficient colon cells. The results showed that RAc is not essential for TRAIL plus Smac
mimetic–induced apoptosis (Fig. 10A). This suggests that KRAS may modulate the
expression of TRAIL receptors as RAc does in the APC deficient colon cells. I tested this
possibility by examining TRAIL receptor expression by Western blot. Expression of mutant
KRAS induced the expression of DR4 and DR5 (Fig. 10B). Mutant KRAS also significantly
inhibited the expression DcR2 (Fig. 10B). These results indicate that expression of mutant
KRAS enhances the DR4/5 expression while repressing the DcR1/2 expression, which
facilitates TRAIL signaling. In other words, mutant KRAS exerts a similar effect on TRAIL
receptors to that of RAc and thus eliminates the need for adding RAc to TRAIL plus Smac
mimetic for the induction of apoptosis in mutant KRAS cells.
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Figure 10. Modulation of TRAIL-receptor expression by KRAS. A, RAc did not
enhance TRAIL- and Smac mimetics–mediated apoptosis in HBE4 cells expressing
mutant KRAS. B, Effect of KRAS activation on the TRAIL receptors DR4, DR5, DcR1,
and DcR2. HBE4 cells were infected with either vector or mutant KRAS-expressing
retrovirus.

3.3 Sensitization to TRAIL plus Smac mimetic mainly depends on the activation of the
MAPK/ERK pathway.
KRAS functions as an upstream activator of RAF-MEK-ERK and PI3K-Akt signaling
pathways, which both can up-regulate the cMyc 25-26. The activation of KRAS signaling may
sensitize normal bronchial epithelial cells to apoptosis induced by TRAIL and Smac mimetic
via cMyc activation. To investigate the role of two major KRAS downstream signaling
pathways (activation of ERK through RAF and of AKT through PI3K) in contributing to TRAIL
plus Smac mimetics–induced apoptosis in mutant KRAS cells, I used MAPK/ERK and AKT
inhibitors or dominant-negative mutants to block the signaling pathways in HBE4-KRAS
stable cells. Induction of dominant-negative mutants of ERK1/2 inhibited KRAS-mediated
ERK activation and TRAIL plus Smac mimetics–induced apoptosis; similarly, U0126, a MEK
inhibitor upstream of ERK, also blocked TRAIL plus Smac mimetics–induced apoptosis via
inhibition of ERK activation (Fig. 11A and 11B). The inhibition of AKT activation by either
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the AKT dominant-negative mutant or Wortmannin, a PI3K inhibitor upstream of AKT, did
not attenuate TRAIL plus Smac mimetics–induced apoptosis (Fig. 11A and 11B). These
results indicate that the sensitization to TRAIL plus Smac mimetics-induced apoptosis is
primarily dependent on activation of the MAPK/ERK pathway.

Figure 11. The ERK/MAPK pathway is essential for KRAS-mediated sensitization.
A, inhibition of KRAS-mediated activation of ERK and AKT. Phosphorylated ERK (pERK) and AKT (p-AKT) were assessed in HBE4-KRAS cells transfected with a
dominant-negative AKT mutant (AKTDN) or ERK1/2 dominant-negative mutants
(ERKDN) or vector (control), or in these cells treated with the PI3K inhibitor
Wortmannin (200 nmol/L) or the dual MEK1 and MEK2 inhibitor U0126 (10
mmol/L) or control (dimethyl sulfoxide, DMSO). B, TRAIL- and Smac mimetics–
mediated apoptosis was attenuated by ERKDN and MEK1/2 inhibitors. The
dominant-negative mutant transfected or inhibitors treated HBE4-KRAS cells were
treated with TRAIL and Smac mimetics for 24 hours. Apoptotic cells (Annexin
V+/PI-) were counted. The data represent results from 3 independent experiments.
Averages and SD are shown.
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3.4 Sensitization to TRAIL plus Smac mimetic in oncogenic KRAS–expressing normal
epithelial cells is dependent on the regulation of c-Myc and c-FLIP levels.
Even though previous results indicate that the sensitization to TRAIL plus Smac
mimetics-induced apoptosis is primarily dependent on activation of the MAPK/ERK
pathway, we still do not know if the MAPK/ERK activation regulate the expression of c-Myc,
which in turn inhibits the expression c-FLIP to sensitize cells to TRAIL and Smac mimetics.
So I first analyzed the expression of c-Myc and c-FLIP in mutant KRAS cells. As we predicted,
expression of mutant KRAS resulted in increased levels of c-Myc protein and consequently
decreased levels of c-FLIP protein expression (Fig. 12A). I then sought to confirm the
significant role of c-Myc and c-FLIP in sensitization to TRAIL plus Smac mimetic. To this end,
c-Myc-shRNA was transfected into mutant KRAS cells to knock down c-Myc expression. The
transfection abolished KRAS-mediated induction of c-Myc expression and restored c-FLIP
expression (Fig. 12B). More importantly, knockdown of c-Myc significantly inhibited TRAIL
plus Smac mimetics–induced apoptosis (Fig. 12D). Furthermore, restoring c-FLIP expression
by transfecting a c-FLIP–expression plasmid blocked TRAIL plus Smac mimetics–induced cell
death in mutant KRAS cells (Fig. 12C and 12D). These data support the ability of KRAS to
sensitize normal HBE4 cells to TRAIL and Smac mimetics through activation of c-Myc and
the subsequent repression of c-FLIP expression.
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Figure 12. c-MYC and c-FLIP are involved in TRAIL plus Smac mimetics–induced
apoptosis in mutant KRAS–expressing cells. A, mutant KRAS activates c-MYC and
represses c-FLIP. HBE4 cells were infected with either control or KRAS-expressing
retrovirus. B, c-MYC was knockdown in mutant KRAS-expressing cells. HBE4 cells
were infected with either control or KRAS-expressing virus or were transfected
with c-Myc-shRNA after KRAS infection. C, c-FLIP is overexpressed in in mutant
KRAS-expressing cells. HBE4 cells infected with KRAS were transfected with either
control vector or full length c-FLIP plasmid. D, apoptosis was attenuated by cMYC
knockdown or cFLIP overexpression. HBE4 cells with various infection and
transfection combinations were treated with TRAIL and Smac mimetics. Apoptotic
cells (Annexin V+/PI-) were counted. The data represent results from 3
independent experiments. Averages and SD are shown.
.
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3.5 Smac mimetic overcomes the antiapoptotic activity of XIAP to facilitate TRAILinduced apoptosis.
Previous results had shown that not the single TRAIL or Smac mimetic but
only the TRAIL plus Smac mimetic combination can induced the apoptosis in mutant KRAS
cells. We hypothesize that Smac mimetic could bind to IAPs, release the caspases and
sensitize the mutant KRAS cells to TRAIL induced the apoptosis. But it is also reported that
Smac mimetic could activate NF-κB pathway and increase the autocrine TNFα level which
may also trigger the apoptosis 148-149. So I next examined the target of Smac mimetic in
sensitizing mutant KRAS cells to TRAIL. I first analyzed XIAP expression in mutant KRAS cells
by Western blot. Although expression of XIAP was not significantly affected by mutant
KRAS, significantly high levels of XIAP were detected, suggesting that the anti-apoptotic
activity of XIAP needed to be inhibited to facilitate TRAIL induced apoptosis (Fig. 13A). To
investigate this possibility, I used XIAP-shRNA to inhibit the expression of XIAP in mutant
KRAS cells (Fig. 13A). Knockdown of XIAP sensitized mutant KRAS cells to TRAIL-induced
apoptosis (Fig. 13B), in the absence of Smac mimetic. These results support the role of
Smac mimetic in targeting the anti-apoptotic activity of XIAP to facilitate TRAIL induced
apoptosis. This sensitization is independent of intrinsic pathway of apoptosis.
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Figure 13. Role of XIAP in TRAIL plus Smac mimetics–induced apoptosis in
oncogenic KRAS–expressing cells. A, effect of XIAP knockdown. HBE4 cells were
infected with either control or mutant KRAS-expressing virus or were transfected
with XIAP-shRNA after KRAS infection. B, induction of apoptosis. HBE4 cells with
various infection and transfection combinations were either treated with TRAIL or
not treated. Apoptotic cells (Annexin V+/PI-) were counted. The data represent
results from 3 independent experiments. Averages and SD are shown.

3.6 Apoptosis induced by the combination of Smac mimetic and TRAIL treatment is
independent of intrinsic apoptotic pathway.
It is reported in the literature that caspase 8/10 can cleave BID via TRAIL
binding to death receptor and formation of the DISC complex 114. The cleaved form of BID,
tBID, can activate the intrinsic pathway by penetrating the mitochondria membrane and
release a group of pro-apoptotic proteins from mitochondria, such as Cytochrome-c and
Smac. Pro-apoptotic proteins other than Smac may also contribute to the TRAIL induced
apoptosis. To determine whether the intrinsic apoptotic pathway also plays a role in the
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apoptosis induced by TRAIL in KRAS mutant cells, Bcl2 and Bcl-xL constructs were
transfected into mutant KRAS HBE4 cells (Fig. 14A). Overexpression of either Bcl2 or Bcl-xL
did not prevent the TRAIL-induced apoptosis (Fig. 14B). These results suggest that the
apoptosis activated by TRAIL and Smac mimetic is independent of mitochondrial apoptotic
pathway.

Figure 14. Overexpression of Bcl2 or Bcl-xL in KRAS mutant HBE4 cells did not
rescue the cells from death. A, HBE4 cells were transfected with either vector or
Bcl2 or Bcl-xL constructs after KRAS infection. B, Induction of apoptosis. HBE4 cells
with various infection and transfection combinations were either treated with
TRAIL or not treated. Apoptotic cells (Annexin V+/PI-) were counted. The data
represent results from 3 independent experiments. Averages and SD are shown.
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3.7 Induction of carcinogenesis in a mouse model of KRAS driven lung cancer.
Previous results have showed that activation of KRAS specifically sensitizes
normal lung epithelial cells to the induction of apoptosis by the combination of TRAIL and
Smac mimetic in vivo. To further test the effect of TRAIL and Smac mimetic-mediated
apoptosis for chemoprevention, we first needed to establish a mouse model with KRAS
activation, which mimics the process of carcinogenesis in humans. For this purpose, I chose
a mouse model of mutant KRAS (KRAS-G12D)–driven lung adenocarcinoma. KRAS-G12D
mice carry a conditional allele of oncogenic KRAS-G12D (LSL-KRAS-G12D) and closely
mimics the tumorigenesis initiated in humans through somatic KRAS mutation 150. LSLKRAS-G12D contains a floxed transcriptional stop element, and infecting the lungs of these
mice with AdenoCre virus, a recombinant adenovirus expressing the Cre recombinase,
resulted in the expression of mutant KRAS and the development of epithelial hyperplasia of
the bronchioles, adenomas, and eventually pulmonary adenocarcinoma 150. Using the dose
of AdenoCre virus mentioned before, I sacrificed the mice at 3 wks and 6 wks post-infection
(Fig. 15A). Then their lungs were inflated with formalin and fixed in formalin overnight.
Lung sections were analyzed by hematoxylin and eosin (H&E) staining. The histology results
show the different stages of carcinogenesis in lung tissue (Fig. 15B). At 3 wks after virus
infection, there are only a few hyperplasias while the uninfected lung is free of hyperplasia
as the red arrows indicated. At 6 wks after virus infection, the number of hyperplasias
continues to increase and there are some areas containing adenoma-like hyperplasia as the
yellow arrows indicated.
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Figure 15. A KRAS lung tumor mice model was established to test the effect of
TRAIL and Smac mimetic. A, The mice were infected with AdCre-CaPi
coprecipitates (5 - 108 pfu) intranasally in two 62.5-mL instillations. Six weeks after
infection, the mice were treated either by 3 time continuous treatments or by
intermittent treatment, 3 continuous injections a cycle, 3 weeks a cycle, totally 3
cycles. B, the mice were sacrificed before the infection or 3wks or 6 wks after the
infection. The lung sections were analyzed by hematoxylin and eosin (H&E)
staining.
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3.8 Short-term continuous TRAIL and Smac mimetic treatment inhibits lung tumor growth
in KRAS transgenic mice.
As TRAIL plus Smac mimetic induces apoptosis in oncogenic KRAS–
expressing cells in vitro, this combination has the potential for chemoprevention through
short term and intermittent therapy. I tested this potential in vivo beginning 6wks after the
induction of lung carcinogenesis. The mice received 3 consecutive injections of TRAIL plus
Smac mimetics within 1 week. Then the mice were sacrificed 1 day following the treatment,
and the lungs were examined for evidence of tumors by H&E staining. I used cleaved
caspase-3 immunohistochemistry to evaluate induction of apoptosis. TRAIL plus Smac
mimetic induced a significant level of apoptosis in lung tumor cells (Fig. 16A). There was no
evidence of apoptosis in normal lung sections (Fig. 16A). Treated mice had a significantly
decreased number of lung lesions (hyperplasias and adenomas; versus control mice; Fig.
16B). The most dramatic decrease was a 97% reduction in advanced lung lesions
(adenomas; Fig. 16B). Therefore, short-term treatment with TRAIL and Smac mimetic
inhibited in vivo lung tumor growth.

3.9 Intermittent TRAIL and Smac mimetic treatments strongly inhibit lung tumor growth
in KRAS transgenic mice.
To test the effect of intermittent TRAIL and Smac mimetics treatment, I
treated the mice with 3 cycles of the 3-perweek consecutive treatments within 2 months.
The mice were sacrificed 3 days after the last treatments, and the lungs were examined for
evidence of tumors by H&E staining. At the time of analysis, most lesions in control mice
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were adenomas, whereas most lesions in treated mice were hyperplasias (Fig. 16C). A
minor, but statistically significant, reduction was observed in the total number of lung
lesions in the treatment group (versus controls; Fig. 16D). More important, the number of
advanced lesions (adenomas) was greatly reduced in the treatment group (versus controls;
Fig. 16D). The lower number of total lung lesions in Figure 16D compared to that in Figure
16B is likely due to the presence of some adenomas, which were more numerous in Figure
16D, comprising multiple hyperplastic lesions. These results support the ability of TRAIL
plus Smac mimetic to induce apoptosis in mutant KRAS cells in vivo and support the
potential of this combination for therapy-like chemoprevention of human lung cancer.
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Figure 16. Effect of TRAIL and Smac on KRAS-induced lung tumors in mice. A,
TRAIL and Smac mimetic induce apoptosis in lung tumors of LSL-KRASG12D mice.
LSL-KRAS-G12D mice were infected with AdenoCre and treated 6 weeks later with
PBS (control; n ¼ 6) or received 3 consecutive treatments with TRAIL (3 mg/kg)
plus Smac mimetics (3 mg/kg; n ¼ 6) within 1 week. Mice without infection were
used as normal controls. Three days after the last treatment, the lung sections
were stained with an anti–cleaved caspase 3 antibody. Representative
photomicrographs are shown. Caspase 3 staining was detected only in
TRAIL/Samc-mimetics treated tumor samples. B, TRAIL and Smac mimetics
treatment inhibits lung tumor growth. Lung sections were stained with H&E and
lung lesions were counted. The data are derived from counting within serial
sections in each mouse. Averages and SD are shown. *, P < 0.05; **, P < 0.001. C,
Intermittent treatment with TRAIL plus Smac mimetics inhibits adenoma
formation. LSL-KRAS-G12D mice were infected with AdenoCre. Six weeks later, the
mice ( n = 6 for each treatment group) were subjected to 3 rounds of intermittent
treatment in 2 months with either PBS (control) or TRAIL (3 mg/kg) plus Smac
mimetics (1.5 mg/kg). Lung sections were stained with H&E; representative
photomicrographs are shown. D, Quantification of lung lesions. Serial sections
were stained with H&E, and lung lesions were counted. The data are derived from
counting within serial sections in each mouse. Averages and SD are shown. ***, P
< 0.0001.
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In this chapter, we observed that the combination of TRAIL and Smac
mimetic specifically induce apoptosis in KRAS activated normal cells. The induction of
apoptosis did not require the attendance of RAc because KRAS activation modulates the
expression TRAIL receptors as RAc did. The KRAS activation sensitize the normal epithelial
cells to TRAIL plus Smac mimetic induced apoptosis by modulating the expression of c-MYC
and c-FLIP through the MAPK/ERK pathway. And in the process, Smac mimetic overcomes
the anti-apoptotic activity of XIAP to facilitate TRAIL-induced apoptosis.
Then I established a mouse model of mutant KRAS (KRAS-G12D)–driven lung
adenocarcinoma to mimic the process of carcinogenesis in humans. At 6 wks after virus
infection, the histology analysis showed there were a number of hyperplasias and some
adenoma-like hyperplasia. Then short-term TRAIL and Smac mimetic treatments strongly
induced apoptosis specifically in the hyperplasia area while the intermittent TRAIL and
Smac mimetic treatments dramatically inhibit lung tumor growth in mice.
Combined in vitro and in vivo results showed that TRAIL and Smac mimetics
treatment can specifically and efficiently induced apoptosis in KRAS activated normal lung
epithelial cells which could mimic the premalignant cells. The long term intermittent
treatment results strongly suggest that this approach could be applied for SITEP based
chemoprevention.
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CHAPTER 4 Use TRAIL and Smac mimetic for lung cancer treatment

Previous results have shown that for the first time a synthetic lethal
interaction among TRAIL, Smac, and constitutive activation of RAS in premalignant
bronchial epithelial cells with great efficiency and specificity. As mutational activation of
KRAS occurs in 25-30% of NSCLC17, targeting oncogenic RAS activation with the
combination of TRAIL and Smac mimetic is a potential new approach for the treatment of
NSCLC. So in this chapter I investigated the mechanism of TRAIL plus Smac mimetics
induced apoptosis in lung cancer cells for NSCLC treatment. I also tested the efficacy of
combination treatment in lung cancer using a tumor xenograft model. Because we also
observed some KRAS mutant lung cancer cell lines are resistant to TRAIL and Smac mimetic
induced apoptosis. The mechanism of resistance to the combination treatment are
explored in some respects.

4.1 TRAIL and Smac mimetic induces apoptosis specifically in KRAS mutant lung cancer
cell line
To determine whether the TRAIL and Smac mimetic combination treatment
can be used to treat lung cancer, I first tested whether the combination treatment was able
to kill lung cancer cell lines. I treated different lung cancer cell lines with and without the
KRAS mutation. The panel of lung cancer cell lines with KRAS mutation includes H460, H358
and H157. The panel of lung cancer cell lines with wild type KRAS includes H322 and H661.
The results indicate that the panel of lung cancer cell lines with KRAS mutation is more
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sensitive to the combination treatment than the panel of lung cancer cell lines with wild
type KRAS (Figure 17A&B).

Figure 17. Effect of TRAIL and Smac mimetic on lung cancer cell lines with or
without mutant KRAS. A, induction of apoptosis in mutant KRAS cell lines
including NCI-H460, NCI-H358 and NCI-H157. B, induction of apopotosis in wild
type KRAS cell lines including NCI-H322 and NCI-H661. Cells were treated with
TRAIL and Smac mimetics. Apoptotic cells (Annexin V+/PI-) were counted. The
data represent results from 3 independent experiments. Averages and SD are
shown.
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4.2 Expression of mutant KRAS sensitize KRAS wild type lung cancer cell lines to TRAIL
and Smac mimetic induced apoptosis.
Previous results showed that the panel of lung cancer cell lines with KRAS
mutation is more sensitive to the combination treatment, which suggest that KRAS
mutation is relative to the positive response. To further confirm whether KRAS activation
sensitizes the KRAS wild type lung cancer cells to TRAIL plus Smac mimetic–induced
apoptosis, I introduced the activating mutant KRASG12V into the KRAS wild type lung cancer
cell line NCI-H322 as previously described for the normal cells. Unsurprisingly, constitutive
expression of mutant KRAS led to activation of downstream signaling pathways, including
phosphorylation of ERK and AKT in NCI-H322 cells (Fig. 18A). As expected, the MAPK/ERK
activation regulate the expression of c-Myc, which in turn inhibits the expression c-FLIP
(Fig.18A). Because previous data also showed that the KRAS activation enhances the DR4/5
expression while repressing the DcR1/2 expression, which facilitates TRAIL signaling. So we
also hypothesize that KRAS activation could modulate the death receptors and decoy
receptors level in NCI-H322 lung cancer cells as in normal lung epithelial cells. But the
western blotting results is not consist with previous results (Fig. 18A). In NCI-H322 cells,
only the DR5 expression level was slightly up-regulated but the DR4 level was not. The
decoy death receptors DcR1/2 were not depressed as in in normal lung epithelial cells.
Then, to test whether KRAS activation sensitizes NCI-H322 lung cancer cells to
TRAIL plus Smac mimetics induced apoptosis, NCI-H322 cells infected with vector or
mutant KRAS retrovirus were treated by Smac mimetic for 30min, then followed by TRAIL
treatment. After 24 hours post TRAIL treatment, the apoptotic cells were determined with
annexin V-FITC apoptosis detection kit. Results showed that NCI-H322 cells infected with
vector virus are resistant to apoptosis induced by TRAIL plus Smac mimetic treatment while
expression of mutant KRAS sensitized part of the cells to TRAIL plus Smac mimetic induced
apoptosis (Fig. 18B). These results suggest that activation of KRAS may specifically sensitize
KRAS wild type lung cancer cell NCI-H322 to TRAIL and Smac mimetic induced apoptosis.
Comparing to the results in normal lung epithelial cells, the apoptosis was induced in only
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about 40% NCI-H322 lung cancer cells even the c-MYC and c-FLIP levels were regulated as
we expected. Considering the death receptors DR4/5 were not up-regulated as in normal
lung epithelial cells, it may suggest that death receptors level are one of the key factors to
decide the cells response to TRAIL plus Smac mimetics induced co-treatment.

Figure 18. Effect of TRAIL and Smac on wild type KRAS lung cancer cell line after
KRAS activation. A, these cells were infected with either vector (vec) or mutant
KRAS expressing retrovirus. Activation of KRAS induct phosphorylation of ERK (pERK) and AKT (p-AKT), activation of c-Myc and repression of c-FLIP by KRAS in NCIH322 cells. The results also showed effect of KRAS activation on the TRAIL
receptors DR4, DR5, DcR1, DcR2 and pro-caspase 8. B, KRAS-mediated H322 cells
were infected with either control or KRAS-expressing retrovirus. H322 cells were
infected with either control or KRAS-expressing retrovirus. B, induction of
apoptosis by TRAIL and Smac mimetics. H322 cells expressing oncogenic KRAS
were treated with TRAIL (100 ng/mL) or Smac mimetics (100 nmol/L) or both or
control (PBS) for 24 hours. Apoptotic cells (Annexin V+/PI-) were counted. The data
represent results from 3 independent experiments. Averages and SD are shown.
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4.3 TRAIL and Smac mimetic mediate tumor growth suppression in KRAS activated lung
cancer xenograft model via induction of apoptosis.
Previous results showed that lung cancer cell lines with KRAS mutation is more
sensitive to the TRAIL plus Smac mimetic treatment. And activation of KRAS also sensitize
KRAS wild type lung cancer cell NCI-H322 to TRAIL and Smac mimetic induced apoptosis.
Those in vitro results showed the efficient anti-tumor effect of TRAIL and Smac
combination treatment. To further test the anti-tumor effect of TRAIL and Smac mimetic in
vivo, I utilized a xenograft tumor model. For this experiment, I injected two different lung
cancer cell lines, NCI-H460 and NCI-H322 into nude mice to generate xenograft tumors.
NCI-H460 cell line harbors mutant KRAS while NCI-H322 has the wild KRAS. This enables a
direct comparison of these two types of lung cancer cell lines with the same treatment.
Since there was no previously published data on the dose of TRAIL and Smac
mimetic for in vivo lung tumor xenograft models, I used the same Smac mimetic dose (3
mg/kg) but doubled the TRAIL dose (6 mg/kg) compared with the transgenic KRAS mice
model. In the NCI-H322 xenograft mice, the growth of tumors was very similar in both
control and treated animals. However, in the mice with NCI-H460 xenograft, the treated
group exhibited decreased tumor growth compared to the control group (Fig. 19A). At the
end of treatment (day 24), the NCI-H322 tumor relative volume increased 8.23 times in
control group versus 9.09 times in the mice treated with TRAIL plus Smac mimetics, while
the NCI-H460 relateive tumor volume increased 8.48 times in control group compared with
only 2.68 times in treated group (Fig. 19B). Despite the small number of animals in this
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study, the difference between NCI-H460 control group and treated group is statistically
significant, and the trend is clear. These in vivo results demonstrate that the combination
of TRAIL and Smac mimetic only demonstrates an anti-tumor effect in the NCI-H460
xenograft tumor model, but not in the NCI-H322 xenograft tumor model. Although these
data are consistent with the in vitro results, I still sought to confirm that the anti-tumor
effect is due to apoptosis induced by the TRAIL and Smac mimetic, and not some other
mechanism. To determine this, TUNEL staining was performed on the xenograft tumor
sections and the results confirm that apoptosis was only induced in the NCI-H460 treated
group, not in either the NCI-H322 treated group or the NCI-H460 control group (Fig. 19C).
These TUNEL results confirm that the anti-tumor effect was accomplished through
apoptosis induced by the TRAIL and Smac mimetic combination treatment.
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Figure 19. The effects of combination treatment in the in vivo xenograft model.
A, xenograft tumor growth curves in control and TRAIL plus Smac mimetic treated
mice. B, the normalized tumor growth fold at the end of treatment (day 24) in
control and TRAIL plus Smac mimetic treated mice. C, the TUNEL staining results
of tumor sections in control and TRAIL plus Smac mimetic treated mice.
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4.4 Resistance in KRAS mutant lung cancer cell lines may be related to the death receptor
expression levels.
Even though TRAIL and Smac mimetic combination treatment exhibited strong
killing effects in vitro and in vivo, it still did not kill all of the cells in vitro and it did not
cause complete regression of the xenograft tumor. This indicates that there may be
additional mechanisms that are inhibiting activation of apoptosis and protecting the cells
from death. To investigate possible mechanisms, I first screened additional lung cancer cell
lines with KRAS mutations. Among those cell lines, I found that the following cell lines are
resistant to TRAIL and Smac mimetic combination treatment to different extents: A549,
NCI-H2122 with KRAS mutation and NCI-H2199 with HRAS mutation (Fig.20A).
To investigate the mechanism of resistance to Smac mimetic and TRAIL
induced apoptosis in KRAS mutant lung cancer cell lines, I first determined the role of
extrinsic and intrinsic apoptosis in response to treatment with TRAIL and Smac mimetic.
Overexpression of either Bcl2 or Bcl-xL did not prevent the TRAIL plus Smac mimeticinduced apoptosis in KRAS mutant lung cancer cell lines NCI-460 and NCI-H358 (Fig. 20B&C).
These results are consistent with what I observed in KRAS activated HBE cells. This data
combined with reports that Smac alone can induce apoptosis independent of Apaf-1/Cyt C
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, I conclude that TRAIL plus Smac mimetic-induced extrinsic apoptosis is sufficient to

trigger downstream caspase activation and cell death, without the involvement of the
intrinsic apoptotic pathway. I next evaluated major components of the extrinsic apoptotic
pathway in those lung cancer cell lines by western blot (Fig. 20D). The results suggest that
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the resistance may not be due to cFLIP and cMyc level as in the HBE cells. In contrast, DR5
and pro-caspase 8 levels are the most likely predictors of responses to TRAIL plus Smac
mimetic induced apoptosis.

Figure 20. The resistance are highly relative to death receptor DR5. A, Induction
of apoptosis. Mutant KRAS cell lines including A549 and NCI-H2122, and mutant
NRAS cell lines NCI-1299, were treated with TRAIL and Smac mimetics. Apoptotic
cells (Annexin V+/PI-) were counted. B, overexpression of Bcl2 and Bcl-xL in NCIH460 and NCI-H358 cells. The Bcl2 and Bcl-xL plasmids were transfected into the
NCI-H460 and NCI-H358 cells. 24 hour after the transfection, cell lysates were
collected. C, induction of apoptosis. NCI-H460 and NCI-H358 with Bcl2 or Bcl-xL
overexpression were either treated with TRAIL plus Smac mimetics or not treated.
Apoptotic cells (Annexin V+/PI-) were counted. D, Comparison of the extrinsic
apoptosis pathway components in different lung cell lines. The levels of death
receptors DR4, DR5 and DcR1; Pro-caspase 8, cFLIP and cMyc are investigated by
western blotting. All the data represent results from 3 independent experiments.
Averages and SD are shown.
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4.5 Increase in DR5 expression via 5Fu stimulation or over-expression can overcome
resistance to TRAIL and Smac mimetic induced apoptosis.
Previous results showed that death receptors DR5 and pro-caspase 8 levels
may determine the cell response to TRAIL and Smac mimetic induced apoptosis. To further
confirm the role of DR5 in determining the response to TRAIL plus Smac mimetic, I
transfected the DR5 construct into 2 resistant cell lines, A549 and NCI-H2122 (Fig. 21A).
The overexpression of DR5 alone induced some apoptosis in NCI-H2122 cells but very little
in A549 cells. However, it can sensitize both A549 and NCI-H2122 to TRAIL plus Smac
mimetic induced apoptosis (Fig. 21B). This result confirmed that the low DR5 level in
resistant cell lines may be a key factor of the resistance to apoptotic induction.
To further study the resistance mechanisms, I also screened the combination
of TRAIL with a panel of anti-tumor drugs for the ability to induce apoptosis in lung cancer
cell lines. I found that 5-Fluorouracil (5Fu) is the best candidate to synergize with TRAIL to
induce apoptosis (Fig. 21C). While studying the mechanism of TRAIL and 5Fu synergy, I
found that 5Fu also up-regulates DR5 levels (Fig. 21D), but not caspase-8 or cFLIP levels
(data not shown here). The mechanism for 5FU up-regulation of DR5 remained unclear.
However, these results still suggest the importance of DR5 in TRAIL induced apoptosis.
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Figure 21. DR5 up-regulation will sensitize the resistant cell lines to TARIL and
Smac mimetics induced apoptosis. A, overexpression DR5 in NCI-H2122 and A549
cell lines. DR5 construct was transfected into NCI-H2122 and A549 cells. Lysated
were collected 24 hours after the transfecdtion. B, cells tranfected with DR5 or
control plasmids were treated with TRAIL (100 ng/mL) or Smac mimetic (100
nmol/L) or both or control (PBS) for 24 hours. Apoptotic cells (Annexin V+/PI-)
were counted. C, cells treated with 5Fu or DMSO were treated with TRAIL (100
ng/mL) or Smac mimetic (100 nmol/L) or both or control (PBS) for 24 hours.
Apoptotic cells (Annexin V+/PI-) were counted. D, the DR5 level in cells treated
with 5Fu increased. The cells were first treated with 5Fu for 24h, then were
treated with TRAIL (100 ng/mL) or Smac mimetic (100 nmol/L) or both or control
(PBS) for another 24 hours. Cell lysates were collected. All the data represent
results from 3 independent experiments. Averages and SD are shown.

In this chapter, to explore the anti-cancer effect of the combination treatment,
I first tested the responses of different lung cancer cell lines to the TRAIL and Smac mimetic
treatment. Results showed that several KRAS mutant lung cancer cell lines are sensitive to
TRAIL and Smac mimetic induced apoptosis while the KRAS wild type lung cancer cell lines
are not. KRAS activation in the KRAS wild type lung cancer cells NCI-H322 can sensitize part
of cells to TRAIL plus Smac mimetic induced apoptosis. In vivo experiment results showed
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that TRAIL and Smac mimetic treatments strongly inhibit mutant KRAS xenograft tumor
growth in mice. All the results suggested that the TRAIL and Smac mimetic combination
treatment has great anti-cancer effect.
But, the TRAIL and Smac mimetic combination treatment can not completely
inhibit the tumor growth in mice. And I also observed that some KRAS or NRAS mutant lung
cancer cell lines are resistant to TRAIL and Smac mimetic induced apoptosis. To enhance
the anti-cancer effect of the approach, I explored the possible mechanism of resistance.
The results suggested that the resistance might be relative to the death receptors level in
lung cancer cells. Further study showed that the resistance could be overcome by 5Fluorouracil or overexpression of DR5. That confirmed the key role of DR5 in determining
the lung cancer cells response to TRAIL induced apoptosis.
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CHAPTER 5 Summaries and Discussion

5.1 Specific targeting of KRAS mutation based on synthetic lethality.
For the first time, my results demonstrate that a synthetic lethal interaction
exists between TRAIL, Smac mimetic, and constitutively active KRAS in premalignant
bronchial epithelial cells and malignant lung cancer cells (Fig. 22). This synergy relied on the
following mechanisms: KRAS up-regulation of c-MYC and thus repressed c-FLIP expression;
KRAS up-regulated death receptors and down-regulated decoy receptors; and Smac
mimetic repression of the apoptotic inhibitory effect of IAPs (particularly XIAP). This
synthetic lethal interaction made it possible to eliminate KRAS-activated premalignant lung
cells or mutant KRAS lung cancer cells using TRAIL plus Smac mimetic with great efficacy
and specificity. Normal cells are not sensitive to the combined treatment because of the
high level of cFLIP and decoy receptors. This is the rationale for pursuing the treatment or
chemoprevention of KRAS mutant lung cancer. As mutational activation of KRAS occurs in
approximately 25-30% of NSCLC and there is currently no good method for treating NSCLC
with KRAS mutation, targeting oncogenic KRAS activation with the combination of TRAIL
and Smac mimeti is potentially a new approach for the therapy and chemoprevention of
NSCLC; this potential is strongly supported by my in vivo animal studies.
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Figure 22. Synthetic lethality targets the KRAS mutant cells. This figure shows
that KRAS activation up-regulates cMYC and thus represses cFLIP; Smac mimetic
inhibits IAPs; KRAS also modulate the Death receptors and decoyed receptors in
unknown mechanism. The synergy can sensitize the cells to TRAIL induced
apoptosis.

5.2 SITEP-based lung cancer chemoprevention via synthetic lethality against KRAS
mutation.
The concept of synthetic lethality is to generate the cell death only when
there are both mutations in synthetically lethal gene pairs, while a single mutation of either
gene is compatible with viability. People have begun using this concept to develop cancerspecific cytotoxic drugs in recent years. There are three advantages of synthetic lethality
for cancer chemoprevention and therapy. First, synthetic lethality focuses on inducing
apoptosis instead of inhibiting some oncogenic pathways, which directly kill the cells in a
short time without leaving creating survival pressure for the cancer cells. This decreases
the possibility of selection of more resistant malignant cancer cells. Second, cancer-specific
mutation makes the associated synthetic lethality interactions very specific and selective.
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The interactions will not harm the normal cells that lack the cancer-specific mutation while
killing of cancer cells with the mutation, which means this approach should improve
toxicity and decrease side effects in patients. Third, while using the synthetic lethality as a
prevention strategy, it is not necessary to constitutively administer agents. Applying
treatment periodically would eliminate the premalignant cells and decrease the cancer risk,
which further decrease the toxicity and the possibility to generate the resistance. These
advantages lead to the idea of short-term intermittent therapy to eliminate premalignancy
(SITEP), which periodically reduces premalignant tumor cell numbers with short
interventions to substantially inhibit or delay cancer development.
Compared to the current chemoprevention strategies, SITEP should reduce
the potential side effects and cost associated with long-term drug administration. It also
could be predicted that the intermittent treatment would decrease the possibility of
generating drug resistance by selectively killing premalignant cells without inducing
metabolic changes in adjacent cells.

5.3 Obstacles to apply this new strategy into clinical trial for KRAS mutant NSCLC
Even though the in vitro and in vivo results showed a promising trend, there
are still a number of obstacles in translating this strategy into clinical trials. Both rhTRAIL
and various Smac mimetics have been tested separately in a series of clinical trials and
showed very little toxicity in patients 125, 145. But that does not guarantee that the
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combination of TRAIL and Smac mimetic are not toxic to patients. Further experiments are
required to evaluate the potential toxicity of this combination.
For the purpose of chemoprevention, not only are powerful killing effects
required, but also low toxicity and few side effects. This means that lower dosage and
longer intervals between the two treatment cycles would be best. To keep the balance of
sufficient killing effect and low toxicity, further research needs to be carried out to test
different dosage combination of TRAIL and Smac mimetic, including additional intermittent
periods and modified TRAIL or agonistic antibodies.
In this project, it is found that KRAS activation can modulate the death
receptors DR4/5 and decoy receptors DcR1/2 level and facilitate the TRAIL triggered
apoptosis. So the attendance of RAc for generating the synthetic lethality with TRAIL and
Smac mimetic is not required here. It is also reported by other literature that DR4/5 levels
are always high in KRAS mutant tumors 151. But the mechanism of KRAS activation regulate
DR4/5 and DcR1/2 remains unclear (Fig. 22). There is study that reported the cMYC can upregulate DR5 level 152. There is also another study that reported the up-regulation of DR5
by KRAS activation depended on P53 153. But the study in my lab showed that cMYC
knockdown did not abolish the modulation of DR5 by KRAS. Also the DR5 levels in different
lung cancer cell lines are not consistent with the condition of KRAS activation or P53 status
(Fig 20). Those results suggested there is unknown mechanism behinds it.
Understanding the regulation mechanism will facilitate application of TRAIL based
treatment or chemoprevention.
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Previous results showed that up-regulation of DR5 by direct overexpression
or indirect stimulus could sensitize the resistant NSCLC cells to TRAIL induced apoptosis.
Those results suggested that DR5 level or DR5/decoy receptor ratio may be the key factor
to determine the cell response upon TRAIL treatment. If we can get the profiles of death
receptors and decoy receptors in the patients, we may predict the patient’s response to
the TRAIL and Smac mimetic combined treatment. Positively modulating the DR5 level also
could be set as the criteria when we screen the possible candidates which may have the
synergetic effects with TRAIL, just like the RAc or 5Fu.
In this project, I introduce the KRASG12V mutant plasmids into normal lung
epithelial cells or wild type KRAS lung cancer cell lines. But the KRASG12V mutation could not
represent all the KRAS mutations because it is reported that there are codon 12, 13
mutations in NSCLC and different mutations on the same codon, such as G12V and G12D
mutations 29. It is reported that different mutations may activate different downstream
signals which means the mutations other than G12V may cause different response of cells
to the TRAIL plus Smac mimetic combination treatment162. So I need to introduce different
KRAS mutations into cells and test the response. This issue also should be concerned for
the animal model, which is KRAS-G12D mice.
Some KRAS mutant lung cancer cell lines showed resistance to synthetic
lethality, while others did not. Resistance may come from the diverse genetic background
of different cancer cells, which is caused by genome instability. I have demonstrated that
the level of death receptors is critical to the response to Smac mimetic. The DR4/5 levels
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are very low in some cell lines. Also the deficiency of downstream key effectors, such as
caspase 8, will protect the cells from TRAIL induced apoptosis. Although NCI-H460 cells are
very sensitive to TRAIL plus Smac mimetic treatment, xenograft tumors of this cell line
cannot be completely inhibited by this combination. One possible explanation is the limited
activity due to very short half-life of the rhTRAIL, only 5-10 minutes when injected i.v. 154.
To overcome this, some groups have tried to use large proteins coupled to TRAIL to
increase its stability. Some progress has been made, but increasing toxicity with this
approach remains a problem 155. Agonistic antibodies to TRAIL-R2 (anti-DR5) have been
tested, but the outcomes are not encouraging 125. This may be due to the poor accessibility
of large antibodies to tumor tissue.
Whether for therapy or chemoprevention, we need to first target a specific
population who are most likely to response to treatment. According to the principle of
synthetic lethality, KRAS mutation is one of the key factors that predict response to Smac
mimetic and TRAIL, but KRAS mutations occur in both tobacco users and non-smoking
patients, which makes selection of a target population more difficult. Among the tobacco
users there are current or prior smokers. Is the KRAS mutation the only criteria for those
different populations? Are other mutations necessary or exclusive for sensitizing cells to
the treatment? Are there any biomarkers or risk factors that can be used to assess the
potential effects? These questions remained unanswered so far and they need to be
addressed in the further development of SITEP.
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5.4 Strategies to overcome resistance.
With continual treatment, it is difficult to avoid the development of
resistance due to the selection of malignant and/or drug-resistant cells. The inherent
genomic instability of cancer allows cells to develop strategies to inhibit cell death, such as
silencing/attenuating death signaling proteins, or over-expression of anti-apoptotic
proteins.
To overcome these blockades, we have to activate death signaling
pathways while inhibiting anti-apoptotic proteins. In the case of TRAIL plus Smac mimetic,
one strategy is to search for agents that modulate the extrinsic signaling molecules. As I
mentioned before, positively modulating the DR5 level could be a standard to screen the
possible candidates, among which is the 5Fu that could up-regulate DR5 expression. The
work in my lab also suggested that 5Fu could increase DR5 distribution on the cell
membrane and some specific region, lipid rafts. The combination of TRAIL and 5Fu showed
more powerful killing effect than the combination of TRAIL and Smac mimetic in vitro and
in vivo, especially in those resistant cell lines (data not shown here)
Even though my studies demonstrated that TRAIL plus Smac induced
apoptosis independently of the intrinsic apoptotic pathway, it is likely that activation of the
intrinsic apoptotic pathway will enhance extrinsic apoptosis. So the addition of agents that
can penetrate the mitochondria may be another good strategy to overcome resistance.
There are several Bcl-2/Bcl-xL inhibitors being studied in clinical trials that may serve as
partners to enhance TRAIL plus Smac mimetic induced apoptosis 163-165.
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5.5 Prospective studies
For the coming next step, I will focus on solving the questions and obstacles
mentioned in the previous discussion part. First we need to completely understand how
KRAS modulate the death receptors and decoy death receptors levels, which might be the
key factor to determine the cell response to TRAIL triggered apoptosis. The work in my lab
had shown that the modulation of death receptors by KRAS is mainly based on the
transcription level. So my lab had cloned different promoter and regulation region of
death receptors into reporter vector. Then we can test which downstream signals of KRAS
mainly accounts for regulating the transcription of death receptors. After understanding
how KRAS modulate the death receptors, we could enhance the modulation and even
sensitize the resistant cell to TRAIL induced apoptosis.
Previous results showed that the premalignant cells or lesions all response
well to the TRAIL plus Smac mimetic treatment while there are more resistances in cancer
cells due to the genome instability. So it suggests that the current approach has more
great potential in cancer prevention other than cancer treatment. But, we should pay more
attention on the concerns of drug selection and drug resistance before applying the current
approach into clinical trials. In this project, I applied the SITEP treatment on the infected
mice for about 3 months and it showed the efficient effect. But the treatment period may
be till not long enough to evaluate the possible accumulating drug resistance. So I plan to
keep the SITEP treatment for longer time and get the Kaplan-Meier survival curves, which
may reveal the possible resistance.

66

Besides the above unsolved issues, one of the most difficult obstacles in
cancer treatment might be the genomic instability, which generate the diverse genetic
background of cancer cells and the resistance to the chemotherapy. So we need a mice
model to investigate if there will be resistance upon to the TRAIL and Smac mimetic
combination treatment after losing the genomic stability. Now in my lab, we have crossed
the conditional P53 knockout mice with LSL-KrasG12D mice. After the mice were infected
with AdenoCre virus, the wild type P53 is knocked out and the mutant KRAS is activated.
The histology analysis showed that the adenoma formed faster after the adenovirus
infection and suggested the tumorigenesis process is accelerated in the mice. So we plan
to use this new model to mimic the genomic instability with KRAS activation to test our
new approach. Previous results have shown that endogenous DR5, cMYC and cFLIP levels
varied in different lung cancer cell lines with KRAS mutation. That also may be due to the
genomic instability. To further investigate how genomic instability will affect the cell
response to the treatment and determine which factors play the key role in sensitizing the
cells to TRAIL induced apoptosis, we will test more lung cancer cell lines and use the
database to analysis the relevance of TRAIL sensitivity and genetic information, such as the
KRAS mutation profiles.
The long term and final goal of these studies is to develop a new approach
for targeting KRAS mutant NSCLC for therapy and chemoprevention. The specificity of this
treatment relies heavily on the activation KRAS. In patients who have a tumor biopsy, it is
not difficult to check the genetic backgrounds of the tumor. Indeed, for patients who have
undergone surgery and are found to have activated KRAS, this strategy may be an effective
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way to eliminate the remaining cancer cells or metastatic cells, and prevent tumor
recurrence. However, in the case of chemoprevention, the question is how to select
patients, or how to identify the high-risk populations? One identifiable group of high risk
people are heavy smokers. It has been reported in numerous studies that KRAS mutation is
always associated with heavy smoking and the frequency of KRAS mutation is high in this
population. So this group might be a good candidate for KRAS targeted chemoprevention.
Further evaluation should be taken on the heavy smokers for the combined treatment.
For the non-smokers or prior smokers, even though the risk of developing
cancer is low, there is still the possibility of spontaneous KRAS mutation. Since the KRAS
mutation is an early event in carcinogenesis and the activation of KRAS will change the
downstream signaling, it is expected that there would be some small change of proteins in
the circulation. These proteins could be used as predictive makers for the success of
synthetic lethality based chemoprevention. The development of microarray techniques and
proteomics makes it possible to identify good targets from blood samples as biomarkers to
predict KRAS mutation or the response to treatment.
The synthetic lethality of TRAIL and Smac mimetic is based on the mutation
but not on the organ site. So this approach could be applied in other cancer types with
common KRAS mutations, such as pancreatic cancer, of which 90% are reported to harbor
KRAS mutations. Besides cancers with KRAS mutation, cancers that are associated with the
activation of growth factor signaling, such as EGFR, which leads to KRAS activation, or
cancers with activated downstream effectors of KRAS, such as BRAF, could also be

68

potential targets for this approach. In support of this some preliminary data from others in
our lab has shown that EGFR mutant lung cancer cell lines are sensitive to the combination
treatment.
In recently years, personalized cancer therapy and cancer prevention have
been a very hot area of research. Synthetic lethality based therapy or prevention could be
an important part of the personalized treatment, which provides a strong effect, low
toxicity and low costs in selected high-risk patients or populations.
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